This approach has substantially improved the pathologic complete response (pCR) rates in early-stage breast cancer (eBC), and has also improved the progression-free survival (PFS) and overall survival (OS) in metastatic cases, making it an important strategy for improving outcomes in patients with HER2-positive breast cancer [3]. The gene discussed is ERBB2; the disease is breast carcinoma.